Kidney Cancer

A Step Forward in the Fight Against Advanced Kidney Cancer

/ Christina Smith / 1 Comment

Photo Courtesy: Allogene Therapeutics Metastatic renal cell carcinoma (RCC) is an advanced form of kidney cancer with few treatment options and a five-year survival rate of less than 17%. With funding support from CIRM, Allogene Therapeutics is developing ALLO-316, an allogeneic CAR-T cell therapy which targets CD70—a protein highly expressed on clear cell renal cell … Continue reading A Step Forward in the Fight Against Advanced Kidney Cancer

Supporting a CAR-T cell trial for kidney cancer

/ California Institute for Regenerative Medicine (CIRM) / Leave a comment

Photo Credit: Allogene Therapeutics. Image of the ALLO-316 allogeneic CAR-T cell therapy. The California Institute for Regenerative Medicine (CIRM) awarded $15 million to Dr. John Le Gall and his team at Allogene Therapeutics. This funding will support the development of ALLO-316, an innovative anti-CD70 CAR-T cell product designed to treat metastatic clear cell renal cell … Continue reading Supporting a CAR-T cell trial for kidney cancer